PFG
HQL

Piershale Financial Group’s abrdn Life Sciences Investors HQL Stock Holding History

Piershale Financial Group’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$11.4K Buy
839
+19
+2% +$262 0.01% 105
2023
Q1 		$11.4K Buy
820
+20
+3% +$286 0.01% 104
2022
Q4 		$11.4K Buy
+800
New +$11.6K 0.01% 105

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
CA
Cornerstone Advisors Asheville, North Carolina $3.04B AUM 36.62% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
RL
RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Piershale Financial Group's HQL Position: Q2 2023 in Review

Piershale Financial Group increased its abrdn Life Sciences Investors (HQL) stake by 2.3% in Q2 2023, buying an estimated $262 and bringing the position to 839 shares worth $11.4K. The position accounts for 0.01% of the portfolio, ranked #105.

Piershale Financial Group first reported a position in HQL in Q4 2022 and has held it in 3 quarters since. The position peaked at $11.4K in Q1 2023. 78 funds tracked by Wall St. Rank hold HQL as of Q2 2023.

  • Piershale Financial Group held 839 shares of abrdn Life Sciences Investors worth $11.4K as of Q2 2023.
  • Piershale Financial Group bought 19 abrdn Life Sciences Investors shares in Q2 2023, an estimated $262.
  • abrdn Life Sciences Investors made up 0.01% of Piershale Financial Group's portfolio in Q2 2023, its #105 holding.
  • Piershale Financial Group first reported a position in abrdn Life Sciences Investors in Q4 2022 and has held it in 3 quarters since.
  • Piershale Financial Group's abrdn Life Sciences Investors position peaked at $11.4K in Q1 2023.
  • 78 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2023.

Based on Piershale Financial Group's 13F filing for Q2 2023, filed 6 Jul 2023.